6 completed, 3 withdrawn, 1 terminated, 1 unknown. 10 Phase 4, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 10 | Completed 6, Withdrawn 2, Terminated 1, Unknown 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Tradjenta: new trials by email Literature Review of Tradjenta trials Research Report on Tradjenta
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus. LIMA association, Tradjenta, Forxiga - Type2 Diabetes Mellitus | Phase 3 | Withdrawn | EMS | 2021-12-01 | 2022-07-27 | |
| Effects of DPP4 Inhibition on COVID-19 Linagliptin, Insulin regimen - Coronavirus Infection, Type 2 Diabetes | Phase 4 | Withdrawn | University of Miami | 2021-06-30 | 2021-06-10 | |
| Efficacy and Safety of Empagliflozin in NODAT Empagliflozin, Linagliptin - New Onset Diabetes After Transplant, Kidney Transplant; Complications | Phase 4 | Terminated | RenJi Hospital | 6 | 2018-07-14 | 2023-11-28 |
| The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products empagliflozin, linagliptin - SGLT-2 Inhibitors, Advanced Glycation End Products | Phase 4 | Withdrawn | Northwell Health | 2017-12-01 | 2018-02-15 | |
| Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES EMPA/LINA 10/5 mg QD (n=22), LINA/EMPA 5/10 mg QD (N=22), Gliclazide 30 mg QD/BID (N=22) - Type2 Diabetes | Phase 4 | Unknown | M.H.H. Kramer | 66 | 2017-11-09 | 2022-01-14 |
| Linagliptin's Effect on CD34+ Stem Cells Linagliptin, Placebo - Type 2 Diabetes, Impaired Renal Function | Phase 4 | Completed | George Washington University | 31 | 2015-04-01 | 2023-01-19 |
| Linagliptin and Mesenchymal Stem Cells: A Pilot Study Linagliptin - Schizophrenia | Phase 4 | Completed | University of Nevada, Reno | 10 | 2015-03-02 | 2020-11-09 |
| The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects Linagliptin, Placebo - Type 2 Diabetes | Phase 4 | Completed | University at Buffalo | 40 | 2014-05-23 | 2023-02-21 |
| ADA Linagliptin in Long Term Care linagliptin, insulin glargine - Diabetes | Phase 4 | Completed | Emory University | 140 | 2014-04-25 | 2018-08-22 |
| Linagliptin Inpatient Trial Linagliptin, Basal Bolus, Linagliptin + 50% Glargine dose on discharge - Type 2 Diabetes | Phase 4 | Completed | Emory University | 295 | 2014-01-01 | 2019-02-20 |
| The Effect of Linagliptin on Mitochondrial and Endothelial Function Linagliptin, Placebo, Microcirculation testing - Type II Diabetes Mellitus | Phase 4 | Completed | Beth Israel Deaconess Medical Center | 45 | 2013-10-01 | 2016-11-18 |
Diabetes Mellitus, Type 2 (7) · Diabetes Mellitus (5) · COVID-19 (1) · Coronavirus Infections (1) · Diabetic Nephropathies (1) · Hyperglycemia (1) · Renal Insufficiency (1) · Schizophrenia (1)
Emory University (2) · Beth Israel Deaconess Medical Center (1) · EMS (1) · George Washington University (1) · M.H.H. Kramer (1) · Northwell Health (1) · RenJi Hospital (1) · University at Buffalo (1) · University of Miami (1) · University of Nevada, Reno (1)
United States (7) · China (1) · Netherlands (1)
Brian Kirkpatrick, MD (1) · Gianluca Iacobellis, MD PhD (1) · Guillermo E Umpierrez, MD (1) · Guillermo Umpierrez, MD (1) · Mark HH Kramer, MD PhD (1) · Ming Zhang, Dr. (1) · Sabyasachi Sen, MD, PhD (1) · Shan Mou, Dr. (1) · Yaomin Hu, Dr. (1) · Zhaohui Ni, Dr. (1)
PMID 27583476, PMID 29289540, PMID 32178593, PMID 32224164, PMID 32493344, PMID 32803882, PMID 41665872